High LDL causes

	Low Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low LDL High LDL
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Prognosis and Complications
Diagnosis
Laboratory Findings
Treatment
Medical Therapy
Landmark Trials
Future or Investigational Therapies
Case Studies
Case #1
High LDL causes On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of High LDL causes All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on High LDL causes
CDC on High LDL causes
High LDL causes in the news
Blogs on High LDL causes
Directions to Hospitals Treating Low density lipoprotein
Risk calculators and risk factors for High LDL causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Rim Halaby, M.D. [3]; Vendhan Ramanujam M.B.B.S [4]

Overview

High LDL can be primary or secondary to diet high in saturated fat, hypothyroidism, nephrotic syndrome, pregnancy, obesity, or medications such as amiodarone, cyclosporine, diuretics, and glucocorticoids.^[1] High LDL can also be caused by inherited diseases that affect the lipid metabolism.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

High LDL does not have any life-threatening cause.

Common Causes

Causes by Organ System

Cardiovascular	No underlying causes
Chemical/Poisoning	Diterpenoids
Dental	No underlying causes
Dermatologic	No underlying causes
Drug Side Effect	Amiodarone, atazanavir, azathioprine, bexarotene, calcineurin inhibitors, chlortalidone, corticosteroids, cyclosporine, desvenlafaxine, diuretics, fish oil supplements, glucocorticoid, immunosuppressive agents, levonorgestrel, lopinavir, Medroxyprogesterone acetate, mycophenolate, nicotine, norgestrel, Norgestrel and Ethinyl estradiol, prednisone, progestin, rapamycin, rosiglitazone, sirolimus, thiazide, tocilizumab
Ear Nose Throat	No underlying causes
Endocrine	Androgens, dehydroepiandrosterone, growth hormone deficiency, hypercortisolism, hypothyroidism, polycystic ovarian syndrome, progestagens, subclinical hypothyroidism, testosterone
Environmental	No underlying causes
Gastroenterologic	Biliary obstruction
Genetic	Acid sphingomyelinase deficiency, autosomal recessive hypercholesterolemia, familial combined hyperlipidemia, familial defective apolipoprotein B-100, familial hypercholesterolemia, IL 28B polymorphisms, Niemann-Pick disease, polygenic hypercholesterolemia
Hematologic	No underlying causes
Iatrogenic	No underlying causes
Infectious Disease	Gram negative bacteremia, H. pylori, small bowel bacterial overgrowth syndrome
Musculoskeletal/Orthopedic	No underlying causes
Neurologic	No underlying causes
Nutritional/Metabolic	Chenodeoxycholic acid, high carbohydrate diet, high saturated fat diet, omega-3 polyunsaturated fatty acids, polygenic hypercholesterolemia, primary hyperlipoproteinemia, primary hypolipoproteinemia, selenium deficiency
Obstetric/Gynecologic	Polycystic ovarian syndrome, pregnancy
Oncologic	No underlying causes
Ophthalmologic	No underlying causes
Overdose/Toxicity	No underlying causes
Psychiatric	No underlying causes
Pulmonary	No underlying causes
Renal/Electrolyte	Chronic kidney disease, nephrotic syndrome
Rheumatology/Immunology/Allergy	Dysproteinemia, lipopolysaccharides, monoclonal gammopathy, paraproteinemia
Sexual	No underlying causes
Trauma	No underlying causes
Urologic	No underlying causes
Miscellaneous	Anorexia, obesity, weight gain

Causes in Alphabetical Order

References

↑ ^1.0 ^1.1 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH; et al. (2014). "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (25 Pt B): 2889–934. doi:10.1016/j.jacc.2013.11.002. PMID 24239923.
↑ ^2.0 ^2.1 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter |month= ignored (help)
↑ ^3.0 ^3.1 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter |month= ignored (help)
↑ Pejic, RN.; Lee, DT. "Hypertriglyceridemia". J Am Board Fam Med. 19 (3): 310–6. PMID 16672684.
↑ Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources

[pmid24239923-1] 1.0 ^1.1 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH; et al. (2014). "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (25 Pt B): 2889–934. doi:10.1016/j.jacc.2013.11.002. PMID 24239923.

[Durrington-2003-2] 2.0 ^2.1 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter |month= ignored (help)

[Covington-2004-3] 3.0 ^3.1 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter |month= ignored (help)

[Pejic--4] Pejic, RN.; Lee, DT. "Hypertriglyceridemia". J Am Board Fam Med. 19 (3): 310–6. PMID 16672684.

[Kronenberg-2005-5] Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter |month= ignored (help)

[1]

[2]

[3]

[4]

[5]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

High LDL causes

Overview

Causes

Life Threatening Causes

Common Causes

Causes by Organ System

Causes in Alphabetical Order

References

Navigation menu